ArticleHuman genomics2026
Linking childhood interstitial lung disease to IARS-related disorder: clinical and preliminary functional studies in four new cases.
Article in Human genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundBiallelic mutations in aminoacyl-tRNA synthetase genes have been implicated in a variety of multisystem disorders. Nonetheless, the correlation between cytosolic IARS (which encodes isoleucyl-tRNA synthetase) and childhood interstitial lung disease (chILD) as well as pulmonary alveolar proteinosis (PAP) has yet to be established.
methodsWe characterized the clinical features of four pediatric patients exhibiting progressive chILD/PAP alongside extrapulmonary manifestations (growth retardation, intellectual impairment, hypotonia, and liver disease). Whole exome sequencing was performed to confirm that biallelic IARS mutations are the etiological cause of the disease, and protein structural prediction was conducted for the identified pathogenic mutations via AlphaFold modeling. Periodic-Acid Schiff (PAS) and Oil-Red O (ORO) staining, along with western blotting and transmission electron microscopy of bronchoalveolar lavage fluid (BALF) and single-cell RNA sequencing (scRNA-seq) of peripheral blood mononuclear cells (PBMCs) were used to characterize the disease phenotype and explore potential pathogenic mechanisms.
resultsAll four patients were confirmed to possess compound heterozygous IARS variants, inherited in trans from unaffected parents. Analysis of BALF revealed characteristic lipoprotein accumulation associated with PAP, evidenced by positive PAS and ORO staining. Additionally, surfactant proteins exhibited abnormal expression, accompanied by notable secondary lysosome formation and vacuolization within alveolar macrophages. scRNA-seq of PBMCs identified a specific depletion of CD14 + CD16+ intermediate monocytes and a transcriptional downregulation of phagosome/lysosome pathways in CD14 + classic monocytes. These findings suggest a potential intrinsic defect in the monocyte/macrophage lineage, potentially contributing to surfactant clearance dysfunction.
conclusionOur findings expand the phenotypic spectrum of IARS-related disorder by identifying chILD/PAP as a core and clinically significant pulmonary manifestation of biallelic IARS mutations. This study establishes IARS as a novel pathogenic gene for chILD/PAP and provides preliminary insights into the immune-related pathogenic mechanisms, highlighting the need for genetic screening of IARS variants in pediatric patients with unexplained respiratory failure and multisystem involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.